Abstract Book - PDF - San Antonio Breast Cancer Symposium

CTRC-AACR San Antonio Breast Cancer Symposium
P2-06-07 Exome sequencing identifies somatic mutations in basal-like
breast cancer before and after neoadjuvant chemotherapy
Jiang Y-Z, Yu K-D, Shao Z-M. Shanghai Cancer Center, Shanghai,
Shanghai, China.
Tumor Cell and Molecular Biology: Genetics - Germline Changes
P2-07-01 BRCA1 regulates RHAMM function in breast cancer
Fleisch MC, Yang Y, Mei Q, Sadat F, Brandi L, Iwaniuk KM, Honisch E,
Maxwell CA, Niederacher D. Heinrich Heine University, Duesseldorf,
Germany; University of British Columbia, Vancouver, BC, Canada.
P6-07-31 Assessing germline Homologous Recombination pathway
deficiency in BRCA1 mutation carriers using Single Cell
Network Profiling
Rosen DB, Leung LY, Louie B, Evensen E, Fields SZ, Cesano A, Shapira
I, Hawtin RE. Nodality Inc, South San Francisco, CA; Monter Cancer
Center, North Shore Long Island Jewish Medical School, Lake
Success, NY.
Tumor Cell and Molecular Biology: Genetics - Somatic Changes
P2-08-01 PIK3CA mutations associate with decreased Ki67 in early
stage breast cancer (BC) and better outcomes in patients even
among those with low Ki67 tumors
Datko FM, Patil S, Kalinsky K, Asher M, Wen YH, Hedvat C, Moynahan
ME. Memorial Sloan-Kettering Cancer Center; Columbia University
Medical Center.
P2-08-02 The large scale structure of the HER-2/neu amplicon in
breast cancer
Pauletti G, Anderson L, Rong H-M, Yu J, Slamon DJ. David Geffen
School of Medicine, University of California, Los Angeles, CA.
P2-08-03 Phosphatidylinositol-3-kinase mutations are common in
lobular neoplasia
Troxell ML, Ang D, Warrick A, Beadling C, Corless CL. Oregon Health
& Science University, Portland, OR.
P2-08-04 HER2 gene status change after taxane based chemotherapy:
be aware of mis-interpretation of polyploidization! Impact for
patient management
Valent A, Penault-Llorca F, Cayre A, Kroemer G. Institut Gustave
Roussy, Villejuif, France; Centre Jean Perrin, Clermont-Ferrand,
France.
Tumor Cell and Molecular Biology: Epigenetics
P2-09-01 Reactivation of epigenetically silenced retinoic acid receptorbeta
for therapy of breast cancer- from molecular mechanism
to potential clinical applications
Ordentlich P, Nguyen N, Jin K, Sadik H, Han L, Sukumar S. Syndax
Pharmaceuticals; Sidney Kimmel Cancer Center, Johns Hopkins
University School of Medicine.
P2-09-02 Epigenetic Regulation of histone variants - a role in hormone
therapy resistant breast cancer?
Nayak SR, Oesterreich S, Pathiraja T. Magee Women’s Research
Institute, University of Pittsburgh Medical Center, Pittsburgh, PA;
Lester & Sue Smith Breast Center, Baylor College of Medicine,
Houston, TX.
P2-09-03 Identifying a landscape of DNA methylation-driven genes in
breast cancer using MethylMix
Gevaert O, Plevritis S. Stanford University.
P2-09-04 DNA methylation landscapes in ER-negative breast cancer
Worsham MJ, Chen KM, Chitale D, Divine G. Henry Ford Health
System, Detroit, MI.
P2-09-05 Screening of significantly hypermethylated genes in breast
cancer using MIRA-based microarray and identifying their
expression levels
Lian Z-q, Wang Q, Li W-p, Zhang A-q, Wu L. Breast Disease Center,
Guangdong Women and Children Hospital of Guangzhou
Medical College.
P2-09-06 The structure design and biological activities of inhibitory
peptides, which block the interactions among polycomb
repressive complex 2
LI KK, Luo L, Kong X, Li L, Luo C. Rui Jin Hospital Affiliated with the
Shanghai JiaoTong University School of Medicine, Shanghai, China;
Shanghai Institute of Materia Medica, Chinese Academy of Sciences,
Shanghai, China.
Prognostic and Predictive Factors: Prognostic Factors - Clinical
P2-10-01 PAM50 gene signature is prognostic for breast cancer patients
treated with adjuvant anthracycline and taxane based
chemotherapy
Liu MC, Pitcher BN, Mardis ER, Davies SR, Snider JE, Vickery T, Reed JP,
DeSchryver K, Singh B, Friedman PN, Gradishar WJ, Perez EA, Martino
S, Citron ML, Norton L, Winer EP, Hudis CA, Perou CM, Ellis MJ,
Barry WT. Georgetown University Lombardi Comprehensive Cancer
Center, Washington, DC; Duke University Medical Center, Durham,
NC; Washington University, St. Louis, MO; Washington University
School of Medicine, St. Louis, MO; New York University Medical
Center, New York, NY; University of Chicago, IL; Robert H. Lurie
Comprehensive Cancer Center, Northwestern University Feinberg
School of Medicine, Chicago, IL; Mayo Clinic, Jacksonville, FL; The
Angeles Clinic and Research Institute, Santa Monica, CA; Hofstra
North Shore-LIJ School of Medicine, ProHEALTH Care Associates,
Lake Success, NY; Memorial Sloan-Kettering Cancer Center, New
York, NY; Dana Farber Cancer Institute, Harvard Medical School,
Boston, MA; Lineberger Comprehensive Cancer Center, University
of North Carolina at Chapel Hill, NC; Siteman Cancer Center,
Washington University School of Medicine, St. Louis, MO.
P2-10-02 Clinical validation of the PAM50 risk of recurrence (ROR) score
for predicting residual risk of distant-recurrence (DR) after
endocrine therapy in postmenopausal women with ER+ early
breast cancer (EBC): An ABCSG study
Gnant M, Filipits M, Mlineritsch B, Dubsky P, Jakesz R, Kwasny
W, Fitzal F, Rudas M, Knauer M, Singer C, Greil R, Ferree S,
Storhoff J, Cowens JW, Schaper C, Liu S, Nielsen T, On behalf of
the ABCSG. Medical University of Vienna, Austria; Medizinische
Universität Salzburg, Austria; A.ö. KH Wr. Neustadt, Wr. Neustadt,
Austria; Hospital of the Sisters of Mercy, Linz, Austria; Nanostring
Technologies, Seattle, WA; Vancouver Hospital, Vancouver, BC,
Canada; MyRAQA Inc, Redwood Shores, CA; Vancouver Coastal
Health, Vancouver, BC, Canada.
P2-10-03 A cross-platform comparison of genomic signatures and
OncotypeDx score to discover potential prognostic/predictive
genes and pathways
Kuderer NM, Barry WT, Geradts J, Ginsburg GS, Lyman GH, Datto
M, Liotcheva V, Isner P, Veldman T, Agarwal P, Hwang S, Ready N,
Marcom PK. Duke University Medical Center, Durham, NC.
P2-10-04 The Mammostrat Test Is an Effective Tool To Stratify Patient
Samples Previously Characterized as Intermediate by the
Oncotype Dx Test
Bloom KJ, Kyshtoobayeva A, Hilaire L, Gutekunst K. Clarient
Diagnostic Services, Aliso Viejo, CA.
P2-10-05 Continuous association of a 200-gene prognostic risk score
with probability of neoadjuvant chemotherapy response and
translation from fresh frozen to FFPE tissue for clinical use
van Laar R, DiPaola J, Carbaugh H, Murphy T, DiRamio A, Flinchum R,
Brown N, Albino T. Signal Genetics, New York, NY.
P2-10-06 Multicenter I-SPY 1 TRIAL (CALGB 150007/150012): Breast
cancer stem cells are associated with intrinsic chemoresistance
and worse survival
Landis MD, Yau C, Neumeister V, Rimm DL, I-SPY 1 TRIAL
Investigators, Esserman L, Chang JC. The Methodist Hospital,
Houston, TX; University of California, San Francisco, CA; Yale
University School of Medicine, New Haven, CT.
Cancer Res; 72(24 Suppl.) December 15, 2012 24s Cancer Research